ulrich medical USA® Announces the Nationwide Commercial Release of the Momentum Posterior Spinal Fixation System

July 14, 2020

ulrich medical USA, Inc., a medical device company focused on developing and commercializing musculoskeletal implant technologies in the United States announced the nationwide commercial release of the Momentum Posterior Spinal Fixation System.

Ulrich Medical USA Chief Commercial Officer Erika Strecker-Laskey said, “After completing hundreds of procedures during the alpha launch, Momentum has already made its mark with an enthusiastic reception and positive reviews from our alpha surgeon users.” She added, “Even amid the healthcare challenges presented by the Covid-19 crisis, we have seen steadily-increasing use of Momentum during this time and a growing demand for more sets.”

Dr. Christopher F. Wagener of Allentown, PA performed multiple procedures with Momentum during the alpha launch period and said, “Momentum gives surgeons exactly what they need, both simplicity and reliability.”

Developed in St. Louis, Missouri, the new Momentum rod-screw system includes polyaxial, reduction, and iliac screws, and is compatible with ulrich medical USA’s neon3® Universal OCT Spinal Stabilization System via transition rods and connectors. This offering allows for surgical constructs capable of bridging from the sacroiliac to the cervical spine.

All screws for the Momentum System are offered in a range of lengths, diameters, and angulations to accommodate unique patient anatomy. Screws are available from Ø 4.5mm to Ø 10.0mm, and in lengths from 25mm to 110mm. The system also offers both titanium and cobalt chrome rods (curved and straight) in Ø 5.5mm and Ø 6.0mm diameters. Single-use drills and taps guarantee consistent instrument performance for optimized clinical results. In addition, specialty surgical instrument modules are available for iliac fixation and deformity (basic) applications.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version